Shanghai - Delayed Quote CNY

Zhejiang Huahai Pharmaceutical Co., Ltd. (600521.SS)

16.26 +0.36 (+2.26%)

At close: October 30 at 3:00:00 PM GMT+8

Chart Range Bar

Loading chart for 600521.SS

Previous Close 15.90
Open 15.85
Bid 16.26 x --
Ask 16.27 x --
Day's Range 15.66 - 16.72
52 Week Range 13.73 - 19.37
Volume 34,449,194
Avg. Volume 31,769,183
Market Cap (intraday) 24.382B
Beta (5Y Monthly) --
PE Ratio (TTM) 25.81
EPS (TTM) 0.63
Earnings Date --
Forward Dividend & Yield 0.10 (0.62%)
Ex-Dividend Date Jun 18, 2026
1y Target Est 18.83

Zhejiang Huahai Pharmaceutical Co., Ltd. engaged in the research, development, production, and sales of generic drugs, biologics, drugs, and specialty active pharmaceutical ingredients in multiple dosage forms in China and internationally. The company offers central neurological, cardiovascular, anti-viral, and other products, as well as APIs and intermediates. It also provides packaging components, such as polyethylene bottles and polypropylene caps for pharmaceuticals. In addition, the company offers contract manufacturing and other services, as well as import and export trade services. Zhejiang Huahai Pharmaceutical Co., Ltd. was founded in 1989 and is headquartered in Linhai, China.

www.huahaipharm.com

8,797

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Drug Manufacturers - Specialty & Generic

Industry

Trailing total returns as of 10/30/2026, which may include dividends or other distributions. Benchmark is SSE Composite Index (000001.SS) .

YTD Return

600521.SS

3.51%

SSE Composite Index (000001.SS)

9.32%

1-Year Return

600521.SS

12.81%

SSE Composite Index (000001.SS)

9.73%

3-Year Return

600521.SS

4.04%

SSE Composite Index (000001.SS)

19.11%

5-Year Return

600521.SS

7.43%

SSE Composite Index (000001.SS)

1.46%

Earnings Per Share (GAAP)

Revenue vs. Earnings

yearly Annual

quarterly Quarterly

yearly Annual

quarterly Quarterly

Q3 FY26

Revenue 2.51B

Earnings --

Profit Margin 0.00%

FY25

FY26

500M

0.0%

Analyst Price Targets

14.00 Low

18.83 Average

16.26 Current

21.50 High

Analyst Recommendations

Strong Buy
Buy
Hold
Underperform
Sell

Valuation Measures

  
  
 Annual 

Market Cap
Enterprise Value
Trailing P/E
Forward P/E
PEG Ratio (current)
Price/Sales (ttm)
Price/Book (mrq)
Enterprise Value/Revenue
Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

Profit Margin

9.85%
Return on Assets (ttm)

3.54%
Return on Equity (ttm)

9.19%
Revenue (ttm)

9.6B
Net Income Avi to Common (ttm)

945.75M
Diluted EPS (ttm)

0.63

Balance Sheet and Cash Flow

Total Cash (mrq)

2.26B
Total Debt/Equity (mrq)

82.54%
Levered Free Cash Flow (ttm)

-283.31M

600535.SS Tasly Pharmaceutical Group Co., Ltd

13.82 +1.54%

600511.SS China National Medicines Corporation Ltd.

27.90 +0.43%

600436.SS Zhangzhou Pientzehuang Pharmaceutical Co., Ltd.

128.59 +0.95%

600518.SS Kangmei Pharmaceutical Co., Ltd.

1.2800 +1.59%

600196.SS Shanghai Fosun Pharmaceutical (Group) Co., Ltd.

22.66 +1.57%

U.S. markets closed

Zhejiang Huahai Pharmaceutical Co., Ltd. (600521.SS)

-2.81%

-0.49%

-0.18%

-4.18%

-13.42%

-11.77%

1,021.69%

Zhejiang Huahai Pharmaceutical Co., Ltd. Overview Drug Manufacturers - Specialty & Generic / Healthcare

Full Time Employees

Fiscal Year Ends

Sector

Industry

Recent News

Performance Overview

YTD Return

1-Year Return

3-Year Return

5-Year Return

Earnings Trends

Earnings Per Share (GAAP)

Revenue vs. Earnings

Analyst Insights

Analyst Price Targets

Analyst Recommendations

Statistics

Valuation Measures

Financial Highlights

Profitability and Income Statement

Balance Sheet and Cash Flow

Company Insights

Research Reports

People Also Watch